68.39
price down icon1.00%   -0.69
after-market アフターアワーズ: 69.40 1.01 +1.48%
loading
前日終値:
$69.08
開ける:
$67.885
24時間の取引高:
402.50K
Relative Volume:
0.30
時価総額:
$7.25B
収益:
$628.56M
当期純損益:
$141.82M
株価収益率:
54.28
EPS:
1.26
ネットキャッシュフロー:
$142.60M
1週間 パフォーマンス:
-6.12%
1か月 パフォーマンス:
-7.93%
6か月 パフォーマンス:
+9.79%
1年 パフォーマンス:
+97.89%
1日の値動き範囲:
Value
$67.77
$68.43
1週間の範囲:
Value
$67.77
$73.78
52週間の値動き範囲:
Value
$32.33
$117.33

Corcept Therapeutics Inc Stock (CORT) Company Profile

Name
名前
Corcept Therapeutics Inc
Name
セクター
Healthcare (1163)
Name
電話
650.688.8803
Name
住所
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Name
職員
500
Name
Twitter
Name
次回の収益日
2025-02-17
Name
最新のSEC提出書
Name
CORT's Discussions on Twitter

CORT を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
CORT
Corcept Therapeutics Inc
68.39 7.33B 628.56M 141.82M 142.60M 1.26
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
476.95 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
572.39 60.56B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.64 42.41B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
575.42 34.96B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.83 31.99B 3.81B -644.79M -669.77M -6.24

Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2023-11-06 アップグレード Truist Hold → Buy
2023-04-11 開始されました SVB Securities Market Perform
2023-04-04 開始されました Piper Sandler Overweight
2023-02-15 ダウングレード Jefferies Buy → Hold
2022-08-01 ダウングレード Truist Buy → Hold
2022-07-27 アップグレード Jefferies Hold → Buy
2022-06-27 再開されました Canaccord Genuity Buy
2022-02-02 開始されました Canaccord Genuity Buy
2022-01-28 開始されました Truist Buy
2020-08-05 ダウングレード Jefferies Buy → Hold
2019-09-24 開始されました Jefferies Buy
2019-09-06 開始されました H.C. Wainwright Buy
2019-02-04 ダウングレード B. Riley FBR Buy → Neutral
2018-08-10 繰り返されました Stifel Hold
2018-05-31 ダウングレード Stifel Buy → Hold
2018-03-09 開始されました B. Riley FBR, Inc. Buy
2017-08-31 開始されました Stifel Buy
2017-02-02 開始されました Ladenburg Thalmann Buy
2015-04-21 開始されました FBR Capital Outperform
2014-01-13 ダウングレード Stifel Buy → Hold
2013-08-09 ダウングレード Janney Buy → Neutral
2013-08-09 ダウングレード Ladenburg Thalmann Buy → Neutral
2012-02-21 繰り返されました JMP Securities Mkt Outperform
2010-01-06 アップグレード Ladenburg Thalmann Neutral → Buy
2008-07-17 開始されました Rodman & Renshaw Mkt Outperform
2007-06-21 アップグレード Punk, Ziegel & Co Mkt Perform → Accumulate
すべてを表示

Corcept Therapeutics Inc (CORT) 最新ニュース

pulisher
11:00 AM

Corcept Advances Cancer Drug as Analysts Back Strong Growth Prospects - Yahoo Finance

11:00 AM
pulisher
Jul 22, 2025

What analysts say about Corcept Therapeutics Incorporated stockFree Stock Market Forecast Reports - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What drives Corcept Therapeutics Incorporated stock priceRemarkable growth - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

Corcept Therapeutics Incorporated Stock Analysis and ForecastConsistently outstanding ROI - Autocar Professional

Jul 21, 2025
pulisher
Jul 21, 2025

Is Corcept Therapeutics Incorporated a good long term investmentTriple-digit wealth increases - Autocar Professional

Jul 21, 2025
pulisher
Jul 21, 2025

Corcept Therapeutics (NASDAQ:CORT): A High-Conviction Buy in the Biopharma Sector Amid EPS Growth and Strategic Momentum - AInvest

Jul 21, 2025
pulisher
Jul 21, 2025

Here's Why We Think Corcept Therapeutics (NASDAQ:CORT) Is Well Worth Watching - Yahoo Finance

Jul 21, 2025
pulisher
Jul 21, 2025

Here's How Much You Would Have Made Owning Corcept Therapeutics Stock In The Last 5 Years - 富途牛牛

Jul 21, 2025
pulisher
Jul 20, 2025

Corcept Therapeutics Incorporated (NASDAQ:CORT) is largely controlled by institutional shareholders who own 70% of the company - simplywall.st

Jul 20, 2025
pulisher
Jul 18, 2025

agilon health, LifeStance Health Group, The Pennant Group, Corcept, and Amphastar Pharmaceuticals Shares Plummet, What You Need To Know - TradingView

Jul 18, 2025
pulisher
Jul 17, 2025

FDA approval sought of relacorilant for platinum-resistant ovarian cancer - Rare Cancer News

Jul 17, 2025
pulisher
Jul 16, 2025

M&T Bank Corp Sells 3,530 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World

Jul 16, 2025
pulisher
Jul 15, 2025

Corcept Therapeutics Incorporated (NASDAQ:CORT) Director Daniel N. Swisher, Jr. Sells 2,200 Shares of Stock - Defense World

Jul 15, 2025
pulisher
Jul 15, 2025

Corcept Seeks FDA Approval for Relacorilant in Ovarian Cancer - Yahoo Finance

Jul 15, 2025
pulisher
Jul 15, 2025

Why Corcept Therapeutics Incorporated stock attracts strong analyst attentionShort Term Profit Focus - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How rare disease-focused Corcept Therapeutics expanded into cancerSan Francisco Business Times - The Business Journals

Jul 15, 2025
pulisher
Jul 14, 2025

Corcept seeks FDA approval for ovarian cancer treatment (CORT) - Seeking Alpha

Jul 14, 2025
pulisher
Jul 14, 2025

Corcept Therapeutics' Relacorilant NDA Submission: A Breakthrough in Ovarian Cancer and a Strategic Pivot to Oncology - AInvest

Jul 14, 2025
pulisher
Jul 14, 2025

Corcept Therapeutics Submits New Drug Application to FDA - TipRanks

Jul 14, 2025
pulisher
Jul 14, 2025

Corcept Therapeutics Files New Drug Application for Treatment of Platinum-Resistant Ovarian Cancer - MarketScreener

Jul 14, 2025
pulisher
Jul 14, 2025

Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer - Business Wire

Jul 14, 2025
pulisher
Jul 11, 2025

Corcept Therapeutics’ Korlym Shows Glucose Control, Weight Reduction in Hypercortisolism, Type 2 Diabetes Patients - MSN

Jul 11, 2025
pulisher
Jul 11, 2025

Piper Sandler reiterates Overweight rating on Corcept Therapeutics stock By Investing.com - Investing.com Canada

Jul 11, 2025
pulisher
Jul 06, 2025

Corcept Therapeutics: A New Standard of Care in Ovarian Cancer Emerges - AInvest

Jul 06, 2025
pulisher
Jul 06, 2025

Corcept Therapeutics (CORT) Announces Pivotal Data from Phase 3 ROSELLA Trial - MSN

Jul 06, 2025
pulisher
Jul 05, 2025

13 Best Pharma Stocks to Buy According to Wall Street Analysts - Insider Monkey

Jul 05, 2025
pulisher
Jul 03, 2025

Corcept therapeutics officer Guyer sells $7350 in shares By Investing.com - Investing.com Canada

Jul 03, 2025
pulisher
Jul 03, 2025

Corcept therapeutics officer Guyer sells $7350 in shares - Investing.com

Jul 03, 2025
pulisher
Jul 02, 2025

Adrenocortical Carcinoma Pipeline Therapeutics Gets a Boost With 20+ Active Pharma Players | DelveInsight - The Globe and Mail

Jul 02, 2025
pulisher
Jul 02, 2025

10 Best NASDAQ Growth Stocks to Buy for the Next 3 Years - Insider Monkey

Jul 02, 2025
pulisher
Jun 30, 2025

Corcept Therapeutics (NasdaqCM:CORT) Dropped From Russell 2000 and Growth Index - Yahoo Finance

Jun 30, 2025
pulisher
Jun 29, 2025

Corcept Therapeutics Incorporated(NasdaqCM: CORT) added to Russell Midcap Index - MarketScreener

Jun 29, 2025
pulisher
Jun 24, 2025

Corcept ALS Drug Shows Significant Survival Benefit Despite Missed Primary Endpoint - Yahoo Finance

Jun 24, 2025
pulisher
Jun 23, 2025

Corcept Presents Data from Treatment Phase of CATALYST Trial at American Diabetes Association’s 85 - Business Wire

Jun 23, 2025
pulisher
Jun 16, 2025

$100 Invested In This Stock 20 Years Ago Would Be Worth This Much TodayCorcept Therapeutics (NASDAQ:CORT) - Benzinga

Jun 16, 2025
pulisher
Jun 16, 2025

Corcept reports annual meeting outcomes By Investing.com - Investing.com Canada

Jun 16, 2025
pulisher
Jun 16, 2025

Corcept May 2025 slides: Revenue target of $900-950M amid pipeline advances - Investing.com Canada

Jun 16, 2025
pulisher
Jun 13, 2025

Corcept Therapeutics director Daniel Swisher sells $155k in stock By Investing.com - Investing.com UK

Jun 13, 2025
pulisher
Jun 13, 2025

Corcept Therapeutics director Daniel Swisher sells $155k in stock - Investing.com Australia

Jun 13, 2025
pulisher
Jun 12, 2025

Insider Sell: Swisher Daniel N JR Sells 2,200 Shares of Corcept Therapeutics Inc (CORT) - GuruFocus

Jun 12, 2025
pulisher
Jun 11, 2025

Relacorilant delays ovarian cancer disease progression: Trial data - Rare Cancer News

Jun 11, 2025
pulisher
Jun 06, 2025

Corcept claims survival benefit in ALS despite missed endpoint - PharmaLive

Jun 06, 2025
pulisher
Jun 06, 2025

Mixed Phase II results for Corcept’s dazucorilant - The Pharma Letter

Jun 06, 2025
pulisher
Jun 06, 2025

Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Purchased by Public Employees Retirement System of Ohio - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

Corcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting - afp.com

Jun 05, 2025
pulisher
Jun 05, 2025

Corcept plots future for ALS drug that flunked Phase 2, citing survival analysis - Endpoints News

Jun 05, 2025
pulisher
Jun 05, 2025

Corcept Therapeutics Therapy Fails Primary Goal But Extends Patient Survival In Amyotrophic Lateral Sclerosis Study - Benzinga

Jun 05, 2025
pulisher
Jun 05, 2025

Corcept's mid-stage ALS study fails (CORT:NASDAQ) - Seeking Alpha

Jun 05, 2025
pulisher
Jun 05, 2025

Corcept Presents Results from Phase 2 Study of Dazucorilant in P - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Corcept Therapeutics Says Its ALS Drug Candidate Fails to Meet Primary Goal - marketscreener.com

Jun 05, 2025

Corcept Therapeutics Inc (CORT) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$22.87
price up icon 4.91%
$36.01
price down icon 0.25%
$103.44
price up icon 0.51%
$28.01
price up icon 5.54%
$114.60
price up icon 2.84%
biotechnology ONC
$294.83
price down icon 0.26%
大文字化:     |  ボリューム (24 時間):